Down-Regulation of ATP-Binding Cassette Transporter G1 Expression by Unmethylated Cpg Oligodeoxynucleotides in RAW 264.7 Macrophages
Total Page:16
File Type:pdf, Size:1020Kb
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 43, No. 9, 510-516, September 2011 Down-regulation of ATP-binding cassette transporter G1 expression by unmethylated CpG oligodeoxynucleotides in RAW 264.7 macrophages Jeong Min Seo1, Ji-Young Lee2, Geun Eog Ji3 of ABCG1 protein expression by CpG 2006. In addition, and Ji Chang You1,4 we also determined the protein level of peroxisome proliferator activated receptor γ (PPARγ), which is rec- 1National Research Laboratory of Molecular Virology ognized as a transcriptional activator of ABC trans- Department of Pathology porters, was also reduced by CpG 2006. Thus, these re- The Catholic University of Korea, School of Medicine sults suggest that ABCG1 is specifically down-regu- Seoul 137-701, Korea lated by CpG 2006 in a PPARγ-dependent manner in 2Department of Nutritional Sciences macrophages. University of Connecticut Storrs CT 06269, USA Keywords: atherosclerosis; ATP-binding cassette 3Department of Food and Nutrition transpoters; cholesterol; CpG oligonucleotide; macro- Research Institute of Human Ecology phages Seoul National University Seoul 151-742, Korea 4Corresponding author: Tel, 82-2-2258-7312; Introduction Fax, 82-2-2258-7790; E-mail, [email protected] http://dx.doi.org/10.3858/emm.2011.43.9.058 All plants and animals, including humans, have in- nate defense systems for protection against viral Accepted 6 July 2011 and bacterial invasions. The innate immune sys- Available Online 8 July 2011 tem is initiated by pattern recognition molecules (PRMs) that recognize pathogen-associated mo- Abbreviations: ABCA1, ATP-binding cassette transporter A1; lecular patterns (PAMPs) such as peptidoglycan, ABCG1, ATP-binding cassette transporter G1; CpG ODN, lipopolysaccharide (LPS), and unmethylated cyti- cytidine-phosphate-guanosine oligodeoxynucleotide; LXRα, dine-phosphate-guanosine (CpG) DNA. Recent liver X receptor α; PO, phosphodiester; PPARγ, peroxisome studies have demonstrated that immunostimulation proliferator activated receptor γ; PS, phosphorothioate; TLR, can be induced through toll-like receptor 9 (TLR9) toll-like receptor by synthetic CpG oligodeoxynucleotides (CpG ODNs) as well as bacterial DNA. To date, many studies have demonstrated that synthetic CpG Abstract ODNs containing ‘CpG motifs’ are able to activate dendritic cells, natural killer (NK) cells, monocytes, We have investigated the effect of various forms of macrophages and B cells, inducing the release phosphodiester cytidine-phosphate-guanosine oli- and secretion of various cytokines and immuno- godeoxynucleotides (CpG ODNs) on the production of globulins (Krieg, 1995; Krug et al., 2001; Iwasaki pro-inflammatory cytokines and related genes in RAW and Medzhitov, 2004; Blaas et al., 2009; El Kebir et 264.7 macrophages. Treatment with the CpG ODNs in- al., 2009; Mangsbo et al., 2009; Vollmer et al., creased the expression of tumor necrosis factor α 2009). Lately, it has been being also reported that (TNF-α), IL-6, and inducible nitric oxide synthase but TLRs and their signaling cascades are involved in not interleukin-1β (IL-1β). We also investigated the ef- the perpetuation of a chronic inflammatory milieu that characterizes obesity and high fat feeding fect of CpG ODNs on the expression of ATP-binding (Shoelson et al., 2007; Ajuwon et al., 2009). For cassette transporter A1 (ABCA1) and G1 (ABCG1) these reasons, safety concerns might be raised genes which are known to facilitate cholesterol efflux concerning the use of CpG ODNs as therapeutic from macrophages for anti-atherosclerosis. CpG 2006 agents for patients with diabetes and inflammatory significantly reduced the levels of ABCG1 mRNA as de- arthritis as well as atherosclerosis (Zeuner et al., termined by real-time polymerase chain reaction, 2003). whereas ABCA1 mRNA level was not changed. It has been reported that macrophages may play Western blot analysis further confirmed the reduction a major role in atherosclerosis (Davies, 1996). Down-regulation of ABCG1 by CpG ODNs 511 When the function of macrophages is not properly controlled, they can trigger low-grade inflammation in the artery by producing various pro-inflammatory cytokines, chemokines and enzymes that amplify the progression of atherosclerosis. In addition to eliciting chronic low-grade inflammation, macro- phages are involved in the pathological deposition of cholesterol during atherogenesis as a result of the uptake of modified low-density lipoproteins (LDLs) (van Reyk and Jessup, 1999). Macrophages with cholesterol accumulation become foam cells, a hallmark of the early atherosclerotic lesion (Rigamonti et al., 2008). ATP-binding cassette trans- porter A1 (ABCA1) and G1 (ABCG1) are known to facilitate cholesterol efflux from macrophages to ex- tracellular acceptors such as lipid-free apolipopro- tein A-I (apoA-I) and high-density lipoprotein (HDL). The ability of apoA-I and HDL to stimulate cholesterol efflux from macrophages in the arterial wall represents the first step in reverse cholesterol transport (RCT), a process that transports excess cholesterol from the periphery to the liver for ulti- mate excretion from the body. The role of HDL in the RCT is central to its anti-atherogenic effects (Tall et al., 2008). ABCG1 was recently shown to be capable of mediating an active efflux of cholesterol Figure 1. Expression of pro-inflammatory cytokine, TNF-α induced by and phospholipids in macrophages (Brewer et al., TLR9 agonist CpG ODNs in RAW 264.7 cells. Cells were incubated with or without CpG ODNs for 12 and 24 h. Supernatants were recovered for 2003). each time point and assayed for TNF-α protein secretion by ELISA. (A) In this study, we hypothesized if CpG ODNs Cells were treated with each CpG ODN (15 μmol/ml) for 12 h to evaluate could be involved in regulating the expression of the effects on TNF-α compared with untreated (mock) and CpG 2006(-) ABCA1 or ABCG1 in macrophages, as little is known controls. (B-D) Cells were treated with CpG 1826, which include murine CpG motifs, and CpG 2006 which includes human CpG motifs. The CpG about the regulation of ABC transporter genes by ODNs induced secretion of TNF-α in a time- and dose-dependent CpG ODN. Therefore, we investigated the effec- manner. Values are means ± standard error of the mean (SEM; n = 6). tiveness of CpG ODNs in a phosphodiester form Bars with different letters are significantly different (P < 0.05). (PO-ODNs), to be more biologically relevant, in the modulation of ABCA1 and ABCG1 gene ex- pression as well as in inducing various pro-in- virus-originated CpG ODN (virus CpG), and CpG flammatory cytokine production in RAW 264.7 mur- 1826 all showed a significant increase in TNF-α ine macrophages. secretion, compared to the mock and CpG 2006 (-) (Figure 1A). Among the CpG ODNs that were used in this study, CpG 2006 had the greatest effect on Results TNF-α production in RAW264.7 macrophages and PE2059 showed an effect similar to that of CpG Immuno-stimulatory effect of natural PO-formed 2006. Compared with PE2059, CpG2006 has one CpG ODNs additional nucleotide, T, at the 3'-terminus. In order to verify first the effectiveness of the CpG The fact that CpG 2006, which contains human ODNs used in this study in inducing alledgedly CpG motif sequences GTCGTT, showed a strong known pro-inflammatory cytokines, RAW 264.7 immuno-stimulatory effect even in murine macro- macrophage cells were treated with various CpG phages is consistent with previous findings ob- ODNs (15 μg/ml) for 12 h, along with a negative served with phosphorothioate-modified ODNs (PS- control CpG 2006 (-) and an untreated control ODNs) in primary B cell and isolated murine car- (mock) (Figure 1A). The tumor necrosis factor diomyocytes (Hartmann and Krieg, 2000; Hartmann (TNF)-α concentration in media after the treatment et al., 2000; Knuefermann et al., 2008). Of noted was measured using an enzyme-linked im- interestingly, CpG 2006 elicited a significantly high- munosorvent assay (ELISA). The results showed er pro-inflammatory response than that of CpG that macrophages treated with CpG 2006, PE2059, 1826 which is generally recognized as a murine 512 Exp. Mol. Med. Vol. 43(9), 510-516, 2011 Figure 2. Comparison of TNF-α and IL-1β induction by CpG 1826 and CpG 2006. Both CpG 1826 and CpG 2006 up-regulated TNF-α sig- nificantly but did not alter IL-1β levels compared to LPS (positive control). Cells were treated with 10 μg/ml of each CpG ODN or 0.1 μg/ml LPS for 24 h. Supernatants were recovered and assayed for the secretion of TNF-α (A) and IL-1β (B) by ELISA. CpG ODN. It was observed that CpG 2006 had a more prominent effect on TNF-α production than CpG 1826 for both cases of 12 h and 24 h treat- ments (Figures 1A-1D); the immunostimulatory ef- fect of CpG 2006 was 61.4 % higher than that of CpG 1826 for 24-h treatment at a concentration of Figure 3. Transcriptional modulation of pro-inflammatory genes by CpG 1826 and CpG 2006. CpG 1826 and CpG 2006 induced mRNA levels of 15 μg/ml (Figure 1B). In addition, a 24-h treatment TNF-α (A), IL-6 (B), and iNOS (C). In contrast, the CpG ODNs did not with CpG 2006 ODN (10 μg/ml) (Figure 1D) up-regulate the mRNA level of IL-1β significantly (D). The mRNA levels of showed further induction of TNF-α than a 12-h the indicated genes were quantified by real-time RT-PCR after treating treatment (Figure 1C). Thus, these results demon- macrophages with 10 μg/ml of each CpG ODN or 0.1 μg/ml LPS for 12 h. strate clearly that PO CpG 2006 is able to increase TNF-α expression in a dose- and time-dependent manner and is superior to CpG 1826 for that matter comparison. RAW 264.7 macrophages were in- in RAW 264.7 macrophage cells. cubated with CpG 1826 or CpG 2006 for 12 h, and We also compared the same immunostimulatory the pro-inflammatory genes TNF-α, IL-6 were eval- effect of CpG ODNs with that of LPS at a concen- uated by quantitative real-time PCR (RT qPCR).